Kiniksa Pharmaceuticals International (KNSA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

KNSA Kiniksa Pharmaceuticals International

Watchlist

22.475
-0.115-0.51%

Close Nov 1 16:00 ET

22.475
0.0000.00%

Post 20:02 ET

1.62BMarket Cap-187291P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Kiniksa Pharmaceuticals International, Plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Yahoo FinanceNov 1 10:52 ET
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow JonesOct 30 11:07 ET · Ratings
Kiniksa Pharmaceuticals Analyst Ratings
BenzingaOct 30 10:57 ET · Ratings
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Moomoo NewsOct 30 08:33 ET · Ratings
Kiniksa Pharmaceuticals International | 10-Q: Q3 2024 Earnings Report
SECOct 29 16:21 ET · Announcements
Express News | Kiniksa Pharmaceuticals Shares Are Trading Lower After the Company Announced Worse-than-expected Q3 Financial Results
BenzingaOct 29 13:53 ET

Comments

TrendTrader

Jul 23 11:19

Looking for 30

$Kiniksa Pharmaceuticals International (KNSA.US)$

Moomoo AI

Feb 28 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

KNSA Kiniksa Pharmaceuticals International

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target